No Evidence of Disease Clinical Trial
Official title:
Clinical Protocol for a Double-Blind, Placebo-Controlled, Randomized Dose-Ranging Study of Celecoxib (SC-58635) on the Acute Effect of Human UV-Irradiation
This randomized clinical trial studies if celecoxib will prevent the damaging effects of sunburn in healthy volunteers. Exposure to ultraviolet light can induce erythema, sunburn or skin redness caused by inflammation. Celecoxib may reduce skin damage by blocking enzymes associated with sunburn in healthy volunteers. Studying samples of skin in the laboratory from patients receiving ultraviolet-radiation before and after celecoxib treatment may help doctors learn more about the effects celecoxib has on cells.
Status | Completed |
Enrollment | 45 |
Est. completion date | December 2004 |
Est. primary completion date | September 2001 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - The subject as Fitzpatrick skin type I, II, or III - If the subject is female and of childbearing potential (women are considered not of childbearing potential if they are at least 2 years post-menopausal and/or surgically sterile): - Has been using adequate contraception (e.g., condom, intrauterine device [IUD], diaphragm and spermicide gel combination) since her last menses and will use adequate contraception during the study, AND - Is not lactating, AND - Has had a negative pregnancy test (serum or urine) within 14 days prior to the first dose of study medication - The subject is willing to abstain from the use of non-steroidal anti-inflammatory drugs (NSAIDs) for the duration of the study - The subject is willing to abstain from the use of all topical agents applied to the buttocks for the duration of the study - The subject is willing to participate for the duration of the study - The subject has provided written informed consent prior to administration of any study related procedures Exclusion Criteria: - The subject is currently taking any medication that may alter the sunlight response or cause an adverse reaction - The subject has a history of melanoma, lupus, psoriasis, rosacea, porphyria, photosensitivity disorder, keloid formation, connective tissue disorder, or any disease that would increase the risk associated with study participation - The subject has excessive hair, blemishes, nevi, uneven pigmentation, sunburn or suntan on the buttocks - The subject has sun bathed or used a tanning bed to expose the buttocks within 12 months of admission to the study - The subject has inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), a chronic or acute renal or hepatic disorder or a significant coagulation defect or any other condition which in the investigator's opinion might preclude use of an NSAID (e.g., congestive heart failure) - The subject has an active malignancy of any type or history; subjects who have a history of nonmelanoma skin cancer and have been treated are acceptable; subjects with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years prior to study enrollment are also acceptable - The subject has active or suspected peptic ulceration or gastrointestinal bleeding - The subject has abnormal baseline laboratory test > 1.5 x upper limit of normal (ULN) for serum glutamic oxaloacetic transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), creatinine, and/or blood urea nitrogen (BUN); all other laboratory abnormalities at baseline thought by the investigator to be clinically significant are also basis for exclusion - The subject has received any investigational medication within 30 days prior to the first dose of study medication or is scheduled to receive an investigational drug other than celecoxib during the course of this study - The subject has known hypersensitivity to cyclooxygenase-2 inhibitors, sulfonamides, or NSAIDs - The subject has been previously admitted to this study - The subject has significant medical or psychosocial problems that would make the subject a poor candidate, in the opinion of the principal investigator |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | University of Rochester | Rochester | New York |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent change in erythema | Descriptive statistics such as mean, median and standard deviation will be calculated. An increase of 50% in the UV dose needed to reach the minimal erythema dose (MED) will be considered preliminary evidence of drug activity. The modulation of the biomarkers will be compared to the shift in the erythema response. Summary statistics will be provided for plasma drug levels. | Baseline up to day 25 | No |
Primary | Percent change in PGE2 | Descriptive statistics such as mean, median and standard deviation will be calculated. An increase of 50% in the UV dose needed to reach the MED will be considered preliminary evidence of drug activity. The modulation of the biomarkers will be compared to the shift in the erythema response. Summary statistics will be provided for plasma drug levels. | Baseline up to day 25 | No |
Primary | Percent change in COX-1 | Descriptive statistics such as mean, median and standard deviation will be calculated. An increase of 50% in the UV dose needed to reach the MED will be considered preliminary evidence of drug activity. The modulation of the biomarkers will be compared to the shift in the erythema response. Summary statistics will be provided for plasma drug levels. | Baseline up to day 25 | No |
Primary | Percent change in COX-2 | Descriptive statistics such as mean, median and standard deviation will be calculated. An increase of 50% in the UV dose needed to reach the MED will be considered preliminary evidence of drug activity. The modulation of the biomarkers will be compared to the shift in the erythema response. Summary statistics will be provided for plasma drug levels. | Baseline up to day 25 | No |
Primary | Percent change in proliferative index | Descriptive statistics such as mean, median and standard deviation will be calculated. An increase of 50% in the UV dose needed to reach the MED will be considered preliminary evidence of drug activity. The modulation of the biomarkers will be compared to the shift in the erythema response. Summary statistics will be provided for plasma drug levels. | Baseline up to day 25 | No |
Primary | Percent change in apoptotic index | Descriptive statistics such as mean, median and standard deviation will be calculated. An increase of 50% in the UV dose needed to reach the MED will be considered preliminary evidence of drug activity. The modulation of the biomarkers will be compared to the shift in the erythema response. Summary statistics will be provided for plasma drug levels. | Baseline up to day 25 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01230346 -
Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer
|
N/A | |
Recruiting |
NCT03156309 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Active, not recruiting |
NCT02780401 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Completed |
NCT03725449 -
Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma
|
N/A | |
Completed |
NCT01497431 -
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants
|
Phase 1 | |
Withdrawn |
NCT03120390 -
Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors
|
N/A | |
Completed |
NCT02090933 -
Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers
|
Phase 2 | |
Terminated |
NCT02735512 -
MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
|
||
Completed |
NCT01149096 -
Collection of Bone Marrow From Donors Treated With or Without Filgrastim
|
Phase 3 | |
Completed |
NCT02961790 -
Oxybutynin Chloride in Managing Hot Flashes
|
Phase 3 | |
Completed |
NCT02288416 -
Video-Based Intervention in Reducing Anxiety in Patients Undergoing Lung Cancer Screening
|
N/A | |
Completed |
NCT01698294 -
Biomarkers in Post-Menopausal Women Receiving Flaxseed
|
N/A | |
Completed |
NCT00896974 -
Study of 9cUAB30 in Healthy Participants
|
Phase 1 | |
Terminated |
NCT03284346 -
Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors
|
N/A |